Sofinnova Partners closes US$815M crossover fund to back European life sciences companies

Sofinnova Crossover II builds on the firm’s first crossover fund, which backed several companies that subsequently achieved significant corporate milestones.

FRANCE—Sofinnova Partners has closed its second crossover fund at €725 million (US$815 million), exceeding its initial target to support late-stage life sciences companies in Europe and selected international markets.

The Paris, London and Milan-based venture capital firm will use Sofinnova Crossover II to finance clinical-stage biopharmaceutical and medical technology companies as they advance towards commercialisation.

The fund will primarily target European businesses, while also considering established investment opportunities in the United States and other international markets.

The fund’s close comes amid increasing demand for growth capital in Europe’s life sciences sector.

Although the region continues to produce companies with promising scientific and clinical programmes, securing financing to advance clinical development, expand operations and enter global markets remains a challenge.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said the fund reflects the growing maturity of Europe’s life sciences ecosystem and the need for investors capable of supporting companies through critical development and commercialisation stages.

Previous investments demonstrate crossover strategy

Sofinnova Crossover II builds on the firm’s first crossover fund, which backed several companies that subsequently achieved significant corporate milestones.

These include LimFlow, acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi Kasei; and Amolyt Pharma, acquired by AstraZeneca. Abivax also progressed to a Nasdaq listing.

These investments illustrate the role of crossover financing in helping companies bridge the gap between clinical development and commercial expansion.

Such funding can provide businesses with capital to advance clinical programmes, strengthen their market positions and prepare for strategic transactions or public listings.

Kinam Hong, Partner at Sofinnova Partners, said European life sciences companies increasingly have the scientific capabilities, clinical evidence and management expertise to compete internationally.

He added that the new fund would support emerging industry leaders while maintaining the investment discipline established under its predecessor.

Fund targets 15 companies

Sofinnova Crossover II has already invested in Hemab Therapeutics, CellCentric and Neurent Medical.

The firm expects to build a portfolio of approximately 15 companies over the fund’s investment period, with Europe remaining its primary investment market.

The strategy is led by Partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat and David Evans.

The European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund (EIF), is among the fund’s backers.

The €725 million raise strengthens the availability of growth-stage financing for European biotechnology and medical technology businesses.

It also positions Sofinnova to support companies seeking to advance clinical assets, prepare for commercial launches and attract further international investment.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.

Visited 7 times, 7 visit(s) today

Newer Post

Thumbnail for Sofinnova Partners closes US$815M crossover fund to back European life sciences companies

Charles River expands US bioanalysis capabilities with US$470M Frontage acquisition

Older Post

Thumbnail for Sofinnova Partners closes US$815M crossover fund to back European life sciences companies

Taiwan to showcase integrated healthcare technologies at MEDICA 2026 in Germany

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *